Strata Critical Medical (SRTA): Wall Street Sees 120% Upside While ARK Invest Exits

Key Takeaways

• On April 13, 2026, ARK Invest unloaded 182,767 shares of Strata Critical Medical through two ETFs, totaling approximately $738,378
• This follows a continued selling trend, including over 75,000 shares dumped on April 10
• Strata Critical Medical operates a specialized healthcare logistics network focused on organ transplantation transport services
• Two analysts recently launched coverage with Buy recommendations and $8 price targets
• Consensus analyst target of $9.08 suggests potential gains exceeding 120% from current levels near $4.12

Cathie Wood’s investment firm, ARK Invest, has been systematically trimming its stake in Strata Critical Medical throughout the past several days. The latest transaction occurred on April 13, 2026, when ARK disposed of 182,767 shares via the ARK Autonomous Technology & Robotics ETF and the ARK Space Exploration & Innovation ETF. The total transaction value reached roughly $738,378.

Strata Critical Medical, Inc., SRTA

This wasn’t an isolated transaction. Earlier on April 10, ARK liquidated more than 75,000 shares, with additional sales documented across multiple trading sessions during this timeframe. The activity suggests a strategic repositioning away from the healthcare logistics firm.

Strata Critical Medical operates as a small-capitalization healthcare logistics provider. The company maintains one of America’s most extensive air transportation and surgical service networks dedicated to organ transplant facilities. Management positions the business as the sole comprehensive platform serving the organ transplant logistics sector.

Currently, shares trade at approximately $4.12. The stock finished 2% higher on April 13 and has rallied 51% year-over-year, keeping it within penny stock parameters.

Wall Street Maintains Optimism Amid ARK’s Exit

Contrary to ARK‘s divestment strategy, two prominent Wall Street analysts have recently launched bullish coverage on the stock.

B. Riley’s Yuan Zhi established coverage with a Buy recommendation and set an $8 price objective. Zhi highlighted the company’s dominant positioning within the U.S. organ transplant sector and emphasized its unique status as the sole provider delivering comprehensive logistics solutions in this specialized market.

Meanwhile, Craig-Hallum’s Bill Bonello also initiated coverage with a Buy rating alongside an $8 target. Bonello noted that significant operational improvements implemented over the past twelve months haven’t yet been reflected in the market valuation.

Both analysts anticipate that investor sentiment will strengthen as the company delivers greater financial transparency and demonstrates operational momentum.

The Analytical Consensus

According to TipRanks data, Strata Critical Medical carries a Strong Buy consensus rating, supported by three unanimous Buy recommendations.

The consensus analyst price objective stands at $9.08, representing potential appreciation exceeding 120% relative to the current trading price of approximately $4.12.

Bonello further suggested that existing analyst projections may be understated, indicating the possibility for even greater upside than current estimates reflect.

ARK Invest hasn’t disclosed specific reasoning behind the ongoing share dispositions, and no new purchase activity was recorded on April 13.

Shares settled at $4.12 on April 13, 2026, with three Buy-rated analysts and a consensus price target of $9.08 currently on the books.

The post Strata Critical Medical (SRTA): Wall Street Sees 120% Upside While ARK Invest Exits appeared first on Blockonomi.